Contra Zynerba Pharmac
13F holders, Q1 2026 (March 31)1holders
1new positions
1sold out
$0.00avg. 13F price*
At the end of Q1 2026, 1 institutions reported holding Contra Zynerba Pharmac in their 13F filings, unchanged from Q4 2025. 1 opened new positions and 1 sold out. The largest holder was Ascentis Independent Advisors ($0).
- Company
- Contra Zynerba Pharmac
- CUSIP
- 989CVR022
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q4 2025 → Q1 2026
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $0 |
| Exits | 1 | $0 |
All 13F filers, Q4 2025 → Q1 2026: 23 shares bought and 100 shares sold, net −77 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 1 holders
| Ascentis Independent Advisors | 0.00% | New | 23 | $0 |
"% of holder's portfolio" is CONTRA ZYNERBA PHARMAC's weight in each manager's 13F, not the share of Contra Zynerba Pharmac the manager owns.